Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipratropium/Levosalbutamol FDC in COPD
NCT06040424Phase 3Active, not recruiting
- Sponsor
- Neutec Group
- Start
- Sep 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ipratropium bromide, levalbuterol in chronic obstructive pulmonary disease (COPD), sponsored by Neutec Group. Started Sep 2023; status: active, not recruiting.
02
Drugs
ipratropium bromidelevalbuterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06040424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06040424.